Jazz Pharmaceuticals price target raised to $93 from $75 at Citigroup Citigroup believes the current valuation of Jazz Pharmaceuticals does not reflect the company's growth prospects outside of Xyrem and its ability diversify revenue. Citi raised its price target for Jazz shares to $93 following the company's Q2 results and keeps a Buy rating on the name.
News For JAZZ From The Last 14 Days
Check below for free stories on JAZZ the last two weeks.
Jazz Pharmaceuticals price target raised to $130 from $110 at UBS UBS raised its price target on Jazz Pharmaceuticals to adjust its discount rate to reflect a change in risk premium. The firm notes the company's business continues to perform above expectations and expects additional business activities to diversify the company. Shares are Buy rated.